Skip to main content
. 2021 Aug;8(8):696–707. doi: 10.1016/S2215-0366(21)00158-9

Table 1.

Sociodemographic and clinical characteristics of the participant group

Befriending (n=66) The Feeling Safe Programme (n=64) All participants (n=130)
Age, years 41·3 (12·0) 41·9 (12·3) 41·6 (12·1)
Gender
Women 22 (33%) 30 (47%) 52 (40%)
Men 44 (67%) 34 (53%) 78 (60%)
Ethnicity
White 58 (88%) 52 (81%) 110 (85%)
Black Caribbean 5 (8%) 3 (5%) 8 (6%)
Black African 0 2 (3%) 2 (2%)
Black other 0 1 (2%) 1 (1%)
Indian 1 (2%) 2 (3%) 3 (2%)
Pakistani 1 (2%) 2 (3%) 3 (2%)
Chinese 0 1 (2%) 1 (1%)
Other 1 (2%) 1 (2%) 2 (2%)
Employment
Unemployed 51 (77%) 51 (80%) 102 (79%)
Employed (full-time) 5 (8%) 1 (2%) 6 (5%)
Employed (part-time) 5 (8%) 4 (6%) 9 (7%)
Self employed 0 1 (2%) 1 (1%)
Retired 2 (3%) 2 (3%) 4 (3%)
Student 2 (3%) 2 (3%) 4 (3%)
Housewife or househusband 1 (2%) 3 (5%) 4 (3%)
Marital status
Single 49 (75%) 43 (67%) 92 (71%)
Cohabiting 2 (3%) 0 2 (2%)
Married or in a civil partnership 8 (12%) 18 (28%) 26 (20%)
Divorced 7 (11%) 3 (5%) 10 (8%)
Living situation
Living alone (with or without children) 29 (44%) 23 (36%) 52 (40%)
Living with spouse 10 (15%) 14 (22%) 24 (19%)
Living together as a couple 2 (3%) 2 (3%) 4 (3%)
Living with parents 17 (26%) 10 (16%) 27 (21%)
Living with other relatives 0 4 (6%) 4 (3%)
Living with others (not listed above) 8 (12%) 11 (17%) 19 (15%)
Clinical diagnosis
Schizophrenia 43 (65%) 36 (56%) 79 (61%)
Schizoaffective disorder 9 (14%) 13 (20%) 22 (17%)
Delusional disorder 2 (3%) 2 (3%) 4 (3%)
Psychosis NOS 12 (18%) 13 (20%) 25 (19%)
Medication
Antipsychotic 64 (97%) 61 (95%) 125 (96%)
Antidepressant 47 (71%) 32 (50%) 79 (61%)
Anxiolytic 4 (6%) 7 (11%) 11 (9%)
Mood stabiliser 10 (15%) 8 (13%) 18 (14%)
Hypnotic 7 (11%) 5 (8%) 12 (9%)
Total number of psychotropics 2·6 (1·2) 2·3 (1·3) 2·4 (1·2)
Antipsychotic CPZ equivalent dose (mg per day) 514·1 (412·9) 449·9 (392·7) 482·7 (402·8)

Data are mean (SD) or n (%). CPZ=chlorpromazine. NOS=not otherwise specified.